In HCC, immune checkpoint inhibitors (ICIs), which block proteins including PD-1, PD-L1, and CTLA-4, have emerged as a cornerstone of systemic therapy, but their efficacy is limited by low T cell infiltration [14] and the tumor’s modest mutational burden [15]. Here, CTLA4 is linked to hepatocellular carcinoma.